$NBIX News Banks, hedge funds and what Citi has to tell

New Post Public Reply Private Reply Replies (0) Message Board

Jan 11, 2015 at 11:51 AM

$NBIX News

Banks, hedge funds and what Citi has to tell its rich clients 7:47 a.m. Jan. 13, 2014 - Shawn Langlois
Stock futures gain as S&P 500 looks to halt skid 8:59 a.m. Jan. 7, 2014 - Victor Reklaitis
Yahoo, Palo Alto, Neurocrine are stocks to watch 5:31 a.m. Jan. 7, 2014 - Wallace Witkowski
Palo Alto, Convergys shares rise on acquisitions 5:08 p.m. Jan. 6, 2014 - Wallace Witkowski
Neurocrine Biosciences shares jump 60% on study 4:51 p.m. Jan. 6, 2014 - Wallace Witkowski
Neurocrine Biosciences shares surge on study 4:50 p.m. Jan. 6, 2014 - MarketWatch.com
S&P’s 50-day average remains the technical test 10:10 a.m. July 1, 2013 - Michael Ashbaugh
Volatility spike supports bullish market view 11:07 a.m. June 4, 2013 - Michael Ashbaugh
Volatility spike supports bullish market view 10:59 a.m. June 4, 2013 - Michael Ashbaugh
In focus: Bears trying to gain traction 6:30 p.m. May 29, 2013 - Lawrence G. McMillan
In focus: Awaiting the next move 7:57 p.m. Feb. 6, 2013 - Lawrence G. McMillan
Neurocrine to offer 9.5 mln shares 10:02 a.m. Jan. 19, 2012 - MarketWatch.com
Inspire, Questcor lead drug stocks north 2:55 p.m. April 5, 2011 - Val Brickates Kennedy
Neurocrine climbs on drug update 10:50 a.m. April 5, 2011 - Val Brickates Kennedy
Friday’s biggest gaining and declining stocks 4:31 p.m. Feb. 11, 2011 - Kate Gibson
Mannkind sinks in mixed drug sector 3:20 p.m. Feb. 11, 2011 - Val Brickates Kennedy
Drug stocks inch higher; Cytori slides 2:34 p.m. Oct. 8, 2010 - Val Brickates Kennedy
Neurocrine shares jump on analyst rating 9:07 a.m. Oct. 8, 2010 - Val Brickates Kennedy
Wednesday’s biggest gaining and declining stocks 4:26 p.m. Sept. 15, 2010 - MarketWatch
Neurocrine Biosciences shares up 4% 8:33 a.m. June 17, 2010 - Nick Godt

Seeking Alpha's Biotech Weekly: Gilead Rises With Phenex, Bass's Patent Attack, And More 4:00 p.m. Jan. 9, 2015 - Seeking Alpha
Neurocrine Biosciences Starts A Data-Rich Year On The Right Foot 11:37 a.m. Jan. 9, 2015 - Seeking Alpha
AbbVie Stock Down After Guidance, Downgrade 10:49 a.m. Jan. 9, 2015 - Investors Business Daily
Hottest Healthcare Stocks Now – SEM IPXL RDY ZLTQ 6:15 a.m. Jan. 9, 2015 - InvestorPlace.com
6 Serious Biotech and Health Care Movers 9:37 a.m. Jan. 8, 2015 - 247WallSt.com
Neurocrine Bio up on positive Phase 3 results 8:59 a.m. Jan. 8, 2015 - Seeking Alpha
Hottest Healthcare Stocks Now – NBIX IPXL HALO VRX 5:45 a.m. Jan. 8, 2015 - InvestorPlace.com
Hottest Healthcare Stocks Now – HALO NBIX AMAG ENDP 5:45 a.m. Jan. 7, 2015 - InvestorPlace.com
Our 3 Best Performing Stocks Of 2014 6:52 p.m. Jan. 5, 2015 - Seeking Alpha
15 Biotech Names For 2015 2:37 p.m. Jan. 5, 2015 - Seeking Alpha
What Investors Expect From Neurocrine Biosciences' Next Drug Announcement 1:53 p.m. Jan. 2, 2015 - benzinga.com
Biggest Movers in Healthcare Stocks Now – QGEN BABY ISRG REGN 12:45 p.m. Dec. 31, 2014 - InvestorPlace.com
Hottest Healthcare Stocks Now – ISIS NBIX CLDX EXAS 6:15 a.m. Dec. 26, 2014 - InvestorPlace.com
Commit To Buy Neurocrine Biosciences At $17, Earn 30.2% Annualized Using Options 12:18 p.m. Dec. 24, 2014 - TheStreet.com
5 Stocks With Ugly Operating Margin Growth — NBIX CTEL TSRA NYNY PMFG 2:15 a.m. Dec. 22, 2014 - InvestorPlace.com
Biggest Movers in Healthcare Stocks Now – NLNK MACK ELGX HZNP 3:00 p.m. Dec. 19, 2014 - InvestorPlace.com
2015 Biotech Drug/Stock Outlook: Here's What You Need to Know 9:20 a.m. Dec. 17, 2014 - TheStreet.com
Auspex Drug Reduces Uncontrolled Movements in Huntington's Patients 4:06 p.m. Dec. 16, 2014 - TheStreet.com
5 Stocks With Poor Operating Margin Growth — NBIX CTEL TSRA NYNY PMFG 2:00 a.m. Dec. 15, 2014 - InvestorPlace.com
Biggest Movers in Healthcare Stocks Now – NBIX TECH AZN ISIS 7:30 a.m. Dec. 10, 2014 - InvestorPlace.com

Critical Alerts For Zynga, Neurocrine Biosciences, Yum! Brands, eBay and TrueCar Released By InvestorsObserver 9:31 a.m. Jan. 9, 2015 - PR Newswire - PRF
Neurocrine Biosciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference 1:00 p.m. Jan. 8, 2015 - PR Newswire - PRF
AbbVie Announces Positive Top-Line Results From Phase 3 Study of Investigational Medicine Elagolix in Patients with Endometriosis 8:00 a.m. Jan. 8, 2015 - PR Newswire - PRF
Biotech Equities Update - Biogen Idec, ACADIA Pharma, Halozyme Therapeutics, Neurocrine Biosciences, and Bluebird Bio 8:50 a.m. Dec. 12, 2014 - PR Newswire - PRF
Just Released: New Research on American Airlines, Staples, Cyren, Neurocrine Biosciences, and Cherokee 9:17 a.m. Dec. 11, 2014 - PR Newswire - PRF
Neurocrine Biosciences Announces Expansion of its Clinical Pipeline 8:00 a.m. Dec. 10, 2014 - PR Newswire - PRF
Neurocrine Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference 7:00 p.m. Dec. 4, 2014 - PR Newswire - PRF
Neurocrine to Present at the 2014 Deutsche Bank BioFEST and the 26th Annual Piper Jaffray Healthcare Conference 1:00 p.m. Nov. 25, 2014 - PR Newswire - PRF
Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel 8:01 a.m. Nov. 19, 2014 - BusinessWire - BZX
Neurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference 1:56 p.m. Nov. 12, 2014 - PR Newswire - PRF
Neurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference 1:00 p.m. Nov. 12, 2014 - PR Newswire - PRF
Neurocrine Biosciences, Inc. Announces Appointment of Darin Lippoldt as Chief Legal Officer 7:30 a.m. Nov. 4, 2014 - PR Newswire - PRF
Neurocrine Biosciences to Present at the Nomura Biotechnology Conference 7:00 p.m. Nov. 3, 2014 - PR Newswire - PRF
Neurocrine Biosciences Reports Third Quarter 2014 Results 4:01 p.m. Nov. 3, 2014 - PR Newswire - PRF
Neurocrine Biosciences Receives Breakthrough Therapy Designation for NBI-98854 in Tardive Dyskinesia 6:30 a.m. Oct. 30, 2014 - PR Newswire - PRF
Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2014 Financial Results 3:05 p.m. Oct. 27, 2014 - PR Newswire - PRF
Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 7:35 a.m. Oct. 27, 2014 - PR Newswire - PRF
Neurocrine Announces Initiation Of Phase III Study For VMAT2 Inhibitor NBI-98854 3:05 p.m. Oct. 20, 2014 - PR Newswire - PRF
Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study 3:02 p.m. Oct. 2, 2014 - PR Newswire - PRF
Neurocrine Biosciences, Inc. Announces Appointment of Malcolm Lloyd-Smith as Chief Regulatory Officer 4:20 p.m. Oct. 1, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Fluence Energy Hits Legal Snag: Investors Called to Act

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

TORRAS Cases Balance Protection with Slim Design for 2026

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

D-Wave Investors Must Decide by Dec 15 Class Suit

Facing the Class Action Deadline There's nothing like a looming deadline to stir the pot, and that's exactly what's happening with D-Wave Quantum Inc. (NASDAQ: QBTS) as it faces the heat of a class action lawsuit. Investors who got caught in the slide between February 26, 2026, and August 25, 2026, need to sharpen their pencils and mark December 15, 2026, on their...

BAIC FOTON Eyes African Market with Strategic Moves

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Gildan Activewear Faces Legal Battle Over Alleged Fraud

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Ivonescimab Promises New Hope for Advanced BTC Patients

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...